香港股市 已收市

4D Molecular Therapeutics, Inc. (FDMT)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
21.74+0.04 (+0.18%)
收市價: 04:00PM EST
21.02 -0.72 (-3.31%)
收市後: 04:38PM EST
全螢幕
交易股價資料並非來自所有市場
前收市價21.70
開市21.71
買盤0.00 x 900
賣出價0.00 x 800
今日波幅21.01 - 21.87
52 週波幅5.32 - 26.49
成交量193,732
平均成交量508,178
市值704.211M
Beta 值 (5 年,每月)2.56
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-2.79
業績公佈日2023年3月27日 - 2023年3月31日
遠期股息及收益率無 (無)
除息日
1 年預測目標價37.57
  • Benzinga

    BMO Capital Markets Says 4D Molecular Could Be 'Attractive Acquisition Target'

    BMO Capital Markets initiated coverage on 4D Molecular Therapeutics Inc (NASDAQ: FDMT) with an Outperform rating and a price target of $50. The analyst writes that 4DMT's platform has generated competitive gene therapies and been clinically validated through its five ongoing clinical programs. BMO notes that 4D Molecular Therapeutics' Wet Age-Related Macular Degeneration (wet AMD) program addresses key limitations of approved/investigational therapies and can potentially confer a $5 billion oppo

  • Benzinga

    4D Molecular Therapeutics Shares Jump After Early Data From Wet Age-Related Macular Degeneration Trial

    4D Molecular Therapeutics Inc (NASDAQ: FDMT) announced interim clinical data from cohort 1 of the Phase 1/2 trial of intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD). 4D-150 was safe and well tolerated, with no serious adverse events or dose-limiting toxicities reported. No clinically significant intraocular inflammation, endophthalmitis, retinal vasculitis, retinal artery occlusion, choroidal effusions, and hypotony were reported to date. Also see: 4D Molecular Shares Fall

  • Benzinga

    4D Molecular Shares Fall After Filing For Fabry Disease Trial Amendment

    4D Molecular Therapeutics Inc (NASDAQ: FDMT) said that in June, the company filed a protocol amendment with the FDA for the ongoing Phase 1/2 trial of 4D-310 for Fabry disease. The protocol amendment is intended to expand the eligible patient population, including the addition of female Fabry patients with symptomatic disease. SVB Securities cuts 4D Molecular to Market Perform from Outperform with a price target of $12, down from $28 after the Fabry update. The analyst feels this decision is an